Miraculins Taps Inverness to Commercialize Preeclampsia Biomarkers | GenomeWeb

NEW YORK (GenomeWeb News) – Canadian diagnostic test developer Miraculins said today that it has partnered with Inverness Medical Innovations to commercialize Miraculins' suite of biomarkers for preeclampsia.

Under the collaborative research and option agreement, Inverness, through its Biosite division, will develop tests for Miraculins' panel of 35 biomarkers involved in placenta development and the occurrence of preeclampsia, a potentially fatal pregnancy complication.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.